Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)

Abstract Background Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated with this drug may develop candidias...

Full description

Bibliographic Details
Published in:BMC Oral Health
Main Authors: Bruna Lavinas Sayed Picciani, Arkadiusz Dziedzic, Juliana Tristão Werneck, Marcello Alves Marinho, Thaylla Núñez Amin Dick, Nara Regina Quintanilha, Eliane Pedra Dias
Format: Article
Language:English
Published: BMC 2021-06-01
Subjects:
Oral candidiasis
Secukinumab
Psoriasis
Interleukin 17 inhibitor (anti IL-17)
Online Access:https://doi.org/10.1186/s12903-021-01653-6

Internet

https://doi.org/10.1186/s12903-021-01653-6

Similar Items